Published in Medical Letter on the CDC and FDA, February 24th, 2008
"This proposed decision is a positive development for the advancement of our AbioCor program in the United States," said Michael R. Minogue, Chairman, President and CEO of Abiomed. "This decision by CMS provides momentum towards making the technology available for chronic patients who require bi-ventricular support and have no other treatment options."
CMS proposed coverage with evidence development of artificial heart devices and also proposes to cover artificial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA